body composition comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
== Literature == Kitagaki H (2021). "Medical Application of Substances Derived from Non-Pathogenic Fungi and -Containing". Journal of Fungi. 7 (4): 4. doi:10.3390/jof7040243. PMC 8063943. PMID 33804991. J. E. Smith (6 December 2012). Aspergillus. Springer US. pp. 46ff. ISBN 978-1-4615-2411-3.
1825 The first publication of the Gompertz–Makeham law of mortality that in the simplest form is: p = a + bx. According to the law, the probability of death p is defined as the sum of age-independent component a and the component depending on age bx which with age increases exponentially. If we place organisms in an absolutely protected environment and in this way make the first component negligible, the probability of death will be completely defined by the second component which actually describes the probability to die from aging. 1860s Alfred Russel Wallace writes down what is probably the first evolutionary theory of aging. In notes written sometime between 1865 and 1870, he proposed a wear and tear theory of aging, suggesting that older animals which continue to consume resources, competing with their offspring in an environment with limited food, were disfavored by natural selection. Therefore, he suggested that aging was an evolved trait which allowed an organism's descendants to thrive. 1882 August Weismann puts forward the wear and tear theory of aging independently of Wallace. 1889 Rejuvenation experiment conducted on himself by the French doctor Charles-Édouard Brown-Séquard. He made himself a few subcutaneous injections from the testicles of young dogs and guinea pigs and claimed that the injections were accompanied by significant and long pain, but then he observed an improvement of the physical condition of the organism and increase of mental activity.
=== Self-efficacy === Self-efficacy refers to a belief that one's ability to accomplish a task is a function of personal effort. Low self-efficacy, or a disconnect between ability and personal effort, is associated with depression; by comparison, high self-efficacy is associated with positive change, including overcoming abuse, overcoming eating disorders, and maintaining a healthy lifestyle. High self-efficacy also has positive benefits for one's immune system, aids in stress management, and decreases pain. A related concept, Personal effectiveness, is primarily concerned with planning and the implementation of methods of accomplishment.
Sources: en.wikipedia.org
== See also == TACAMO Boeing EC-135 Boeing E-4 Advanced Airborne Command Post ("Nightwatch") E-6 Mercury Airborne Launch Control System Airborne Launch Control Center Decapitation strike Letters of last resort Dead Hand (Perimeter) Continuity of Operations Plan Single Integrated Operational Plan Nuclear utilization target selection
== Adaptogenic and neuroprotective effects == A neurocytological study of granular cerebellar neurons in culture under conditions of moderate glutamate stress showed that lithium ascorbate is more effective in maintaining neuronal survival than inorganic lithium salts (chloride, carbonate). Under conditions of glutamate stress, lithium ascorbate at concentrations of 0.2–1.0 mM significantly and dose-dependently increased the survival of neurons: the most pronounced neuroprotective effect was observed at an ascorbate concentration of 1 mM (by 11%). The use of lithium ascorbate even at the minimum concentration (0.1 mM) resulted in a significant difference in neuron survival (p=0.049 according to the Kolmogorov-Smirnov test). The use of a non-lithium salt of ascorbic acid (potassium ascorbate) was characterized by a much less pronounced neuroprotective effect. Inhibition of glycogen synthase kinase syntentase-3 (GSK-3) and induction of brain-derived neurotrophic factors are the main mechanisms of the neuroprotective action of lithium salts. In addition, by inhibiting NMDA receptors, lithium ions can regulate calcium homeostasis and inhibit the activation of calcium-dependent apotosis, also showing synergy with neuropeptides.
Amphetamine is also a substrate for the presynaptic vesicular monoamine transporter, VMAT2. Following amphetamine uptake at VMAT2, amphetamine induces the collapse of the vesicular pH gradient, which results in a dose-dependent release of dopamine molecules from synaptic vesicles into the cytosol via dopamine efflux through VMAT2. Subsequently, the cytosolic dopamine molecules are released from the presynaptic neuron into the synaptic cleft via reverse transport at DAT.
Of these 39 odd Z elements, 30 elements (including hydrogen-1 where 0 neutrons is even) have one stable odd-even isotope, and nine elements: chlorine (17Cl), potassium (19K), copper (29Cu), gallium (31Ga), bromine (35Br), silver (47Ag), antimony (51Sb), iridium (77Ir), and thallium (81Tl), have two odd-even stable isotopes each. This makes a total 30 + 2(9) = 48 stable odd-even isotopes. There are also five primordial long-lived radioactive odd-even isotopes, 8737Rb, 11549In, 18775Re, 15163Eu, and 20983Bi. The last two were only recently found to decay, with half-lives greater than 1018 years.
Sources: en.wikipedia.org
Sodium nitrite is a preservative used in lunch meats, hams, sausages, hot dogs, and bacon to prevent botulism and other foodborne pathogens. It serves the important function of controlling the bacteria that cause botulism, but sodium nitrite can react with proteins, or during cooking at high heats, to form carcinogenic N-nitrosamines. It has also been linked to cancer in lab animals. The commonly used sodium benzoate has been found to extend the shelf life of bottled tomato paste to 40 weeks without loss of quality. However, it can form the carcinogen benzene when combined with vitamin C. Many food manufacturers have reformed their products to eliminate this combination, but a risk still exists.
T4 is a haplogroup unique to East Asia that is not observed in Near Eastern, European, and African cattle, and T3 is the predominant haplogroup in European cattle, but T3 is also predominant in Korean cattle. This means that the present breed of Korean cattle is not the main ancestor of the Wagyu. In addition, haplogroup P has additionally been detected in about 46% of the Japanese Shorthorn. It has been detected in many extinct European aurochs, but has only been found in a total of three current livestock cattle—one Chinese and two Korean—out of several thousand individuals in the database. The Japanese Shorthorn was created by crossing the Nanbu cattle bred in the former Nanbu Domain territory in northeastern Japan (present-day Iwate Prefecture) with Shorthorns and other breeds imported from the United States, but P has not been detected in Shorthorns and is thought to be derived from the Nanbu cattle. Fossils of Hanaizumi Moriushi and Aurochs have been found in Iwate Prefecture, but it is unclear if the Nanbu cattle were related to these. Haplogroup P has also been found in Chinese and Korean cattle, but it is extremely rare compared to T4. Therefore, it is suggested that the ancestors of the Nanbu cattle have a different origin from the ancestors of the Japanese Black in western Japan, where T4 is abundant, and that there is no single ancestor of the Wagyu.
=== Evolution === A genetic analysis using cytochrome b, and a multigene analysis showed that the king cobra was an early offshoot of a genetic lineage giving rise to the mambas, rather than the Naja cobras. A phylogenetic analysis of mitochondrial DNA showed that specimens from Surat Thani Province and Nakhon Si Thammarat Provinces in southern Thailand form a deeply genetically divergent clade from those in northern Thailand, which grouped with specimens from Myanmar and Guangdong in southern China.
=== Two common regimens: pens, injection ports, and pumps === One method of intensive insulinotherapy is based on multiple daily injections (sometimes referred to in medical literature as MDI). Meal insulin is supplied by injection of rapid-acting insulin before each meal in an amount proportional to the meal. Basal insulin is provided as a once or twice daily injection of dose of a long-acting insulin. In an MDI regimen, long-acting insulins are preferred for basal use. An older insulin used for this purpose is ultralente, and beef ultralente in particular was considered for decades to be the gold standard of basal insulin. Long-acting insulin analogs such as insulin glargine (brand name Lantus, made by Sanofi-Aventis) and insulin detemir (brand name Levemir, made by Novo Nordisk) are also used, with insulin glargine used more than insulin detemir. Rapid-acting insulin analogs such as lispro (brand name Humalog, made by Eli Lilly and Company) and aspart (brand name Novolog/Novorapid, made by Novo Nordisk and Apidra made by Sanofi Aventis) are preferred by many clinicians over older regular insulin for meal coverage and high correction. Many people on MDI regimens carry insulin pens to inject their rapid-acting insulins instead of traditional syringes. Some people on an MDI regimen also use injection ports such as the I-port to minimize the number of daily skin punctures. The other method of intensive/flexible insulin therapy is an insulin pump. It is a small mechanical device about the size of a deck of cards.
The Sue Golding Graduate Division was established in 1957 to offer Doctor of Philosophy (PhD) degrees in biomedical science. In 1963, Einstein established its Department of Genetics, the first at any at any medical school; the coursework it offered was possibly the first formal medical curriculum on genetics. The following year, the Medical Scientist Training Program (MSTP), a combined MD/PhD program, was established. The first successful coronary artery bypass surgery was performed in 1960 at Einstein by a team led by Robert H. Goetz; the procedure has been described in The Annals of Thoracic Surgery as "one of the most significant surgical achievements of the 20th century". In 1966, the school completed a 375-bed private teaching hospital—now known as the Jack D. Weiler Hospital—with New York City Mayor John Lindsay presiding over its opening. The Ullmann Research Center for Health Sciences, a 12-story facility, opened in 1964. The following year, the Joseph P. Kennedy Jr. Foundation donated $1.45 million to Einstein to establish a center to study human development and mental disabilities. The center, named for Rose F. Kennedy, opened with 200 staff scientists in 1970. Also that year, the college began construction on the 15-story Charles C. and Beulah Bassine Educational Center devoted to public health. Beginning in 1971, aided by a five-year, $12,157,000 federal grant, the college experimented with a 3-year MD degree pathway and increased class sizes.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.